Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I single ascending dose study of RO7189752 in healthy male volunteers
NL-OMON45777Phase 1Active, not recruiting
- Sponsor
- Roche
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in multiple sclerosis (MS) comparing RO7189752 with Placebo (2 arms). Primary endpoint: Safety and tolerability. Started Aug 2018; status: active, not recruiting.
02
Drugs
fenebrutinib
03
Conditions
multiple sclerosis (MS)
Beyond the preview
Go deeper on NL-OMON45777.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON45777.